CN101804150A - Traditional Chinese medicine composite used for treating left ventricular diastolic dysfunction - Google Patents
Traditional Chinese medicine composite used for treating left ventricular diastolic dysfunction Download PDFInfo
- Publication number
- CN101804150A CN101804150A CN 201010128459 CN201010128459A CN101804150A CN 101804150 A CN101804150 A CN 101804150A CN 201010128459 CN201010128459 CN 201010128459 CN 201010128459 A CN201010128459 A CN 201010128459A CN 101804150 A CN101804150 A CN 101804150A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- filtrate
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine composite used for treating left ventricular diastolic dysfunction, which belongs to the technical field of medicines. The traditional Chinese medicine preparation comprises ginseng, astragalus, Savia miltiorrhiza, ophiopogon root, the rhizome of chuanxiong and the like and can be clinically used for treating the left ventricular diastolic dysfunction, and the ginseng is pulverized into fine powder for standby application. The Savia miltiorrhiza or/and Schisandra chinensis is/are extracted twice by backflow with ethanol with the concentration of 85% for 1-3 hours each time and filtered, and the filtrates are combined and concentrated by decompression to obtain alcohol immersing paste; and the rest ophiopogon root, rhizome of chuanxiong, astragalus or/and hawthorn are decocted with water twice for 1-3 hours each time, the decoction liquids are combined and filtered, the filtrate is concentrated and added with equal amount of ethanol with the concentration of 85%, the mixture stands still overnight after being stirred sufficiently, the precipitate is filtered out, the ethanol in the filtrate is recycled, and the filtrate is concentrated to obtain water extracted immersing paste. After the two immersing pastes are combined, ginseng thin powder and appropriate accessories are added to prepare capsules, tablets, drops and granules in accordance with conventional processes.
Description
Technical field:
The present invention relates to a kind of Chinese medicine composition, particularly relate to a kind of Chinese medicine composition and preparation method that is used for the treatment of left ventricle diastolic malfunction.
Background technology:
Left ventricle diastolic malfunction is meant in the normal or slightly impaired patient of contractile function; the syndrome of the congestive heart failure clinical manifestations such as pulmonary venous pleonaemia that caused owing to valve and pericardium illness because left chamber itself is full unusual; at present; along with going deep into of clinical research; left ventricle diastolic malfunction has caused great attention clinically; in case the clinical manifestation heart failure occurs; patient's average life is 5 years; badly influenced patient's quality of life, be referred to as real " noiseless killer ".The patient of chronic cardiac insufficiency can be divided into contractile function and diastolic function incomplete two big classes clinically, though clinical obvious not full patient's the year survival rate of cardiac systolic function that improved in this year, but left ventricle diastolic malfunction patient year survival rate has the tendency of decline on the contrary, and the Therapeutic Principle that modern medicine is taked the left ventricle diastolic malfunction patient is the supply-demand imbalance that improves oxygen, adjust diastole or/and contractile function, usually adopt cerebrocrast thing or Bextra thing, in recent years along with the progress with the cardiovascular molecular biology research of carrying out of the clinical trial of extensive left ventricle diastolic malfunction medicine, said medicine can not satisfy clinical demand, because said medicine still has arguement to the influence of metabolism and target organ damage, and great majority exist certain side effect, the restriction of part its clinical practice.
Tradition Chinese traditional treatment lay special stress on organic conception, determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs, regulating yin and yang, the too many levels conditioning, this and modern medicine have certain advantage to left ventricle diastolic malfunction treatment aspect.Characteristics such as according to this disease sickness rate height, Western medicine control is not satisfied, and Chinese medicine curative effect height, toxic and side effects are little add that we are clinical and study, treat effective experience repeatedly, allow extensive patients be benefited.
Summary of the invention
The objective of the invention is to for clinical provide a kind of new, effectively treat the Chinese medicine composition and preparation method thereof of left ventricle diastolic malfunction.
The present invention is achieved through the following technical solutions:
The crude drug of pharmaceutical composition of the present invention is formed and proportioning following (by weight):
Can also add 13.3 parts-39.9 parts of Fructus Schisandrae Chinensis in 20 parts-60 parts of Radix Ginsengs, 26.7 parts-80.1 parts of Radix Salviae Miltiorrhizaes, 20 parts-60 parts of the Radixs Astragali, 20 parts-60 parts of Radix Ophiopogonis, 13.3 parts-39.9 parts of Rhizoma Chuanxiongs, the above-mentioned crude drug or/and 20 parts-60 parts of Fructus Crataegis.
Optimum ratio is: can also add 26.6 parts of Fructus Schisandrae Chinensis in 40 parts of Radix Ginsengs, 53.4 parts of Radix Salviae Miltiorrhizaes, 40 parts of the Radixs Astragali, 40 parts of Radix Ophiopogonis, 26.6 parts of Rhizoma Chuanxiongs, the above-mentioned crude drug or/and 40 parts of Fructus Crataegis.
The preparation method of foregoing invention medicine is: the Radix Ginseng powder is broken into fine powder, and is standby.Radix Salviae Miltiorrhizae or/and Fructus Schisandrae Chinensis with 85% alcohol reflux secondary, each 1-3 hour, filter, merging filtrate, concentrating under reduced pressure must be carried pure extractum; All the other Radix Ophiopogonis, Rhizoma Chuanxiong, the Radix Astragali are or/and Fructus Crataegi decocts with water secondary, each 1-3 hour, collecting decoction filters, and filtrate concentrates, add equivalent 85% ethanol, after fully stirring, standing over night, elimination precipitate, filtrate recycling ethanol also is concentrated into relative density 1.30～1.36 (80 ℃), gets the water extracted immersing paste.After above-mentioned two kinds of extractum merging, add Radix Ginseng fine powder and appropriate amount of auxiliary materials, make capsule, tablet, drop, granule according to conventional operation.
Can effectively treat left ventricle diastolic malfunction on the clinical drug of the present invention, and have no side effect.
Experimental example one pharmacodynamic experiment
Drug combination preparation main pharmacodynamics result of study of the present invention has confirmed that this pharmaceutical composition has the effect of stronger treatment left ventricle diastolic malfunction.
1.1 case selects diagnostic criteria as follows: 1. clear and definite organic heart disease is arranged.2. the protopathy symptom is arranged as dizzy, uncomfortable in chest, angina pectoris, arrhythmia etc., and do not have clinical symptoms of heart failure such as ponopalmosis, tachypnea, dyspnea.3. ultrasonic examination by Doppler's method/＜1, slope reduces.4. non-invasive cardiac function checks that IRP, RFP, SEP are unusual, and contractile function is normal.According to above diagnostic criteria, make a definite diagnosis asymptomatic left ventricle diastolic malfunction patient 67 examples.Wherein, use beta-blocker treatment patient 17 examples, all adopt oral metoprolol 12.5～25mg/ time, 2 times/day.Use patient's 15 examples of calcium ion antagonist treatment, give oral nitrendipine 10mg/ time according to patient's blood pressure, 2～3 times/day.Patient's 20 examples (capsule) of use medicine composition group treatment 1.2g/ time, 3 times/day.
1.2 observation item
Observe and respectively organize patient treatment front and back ultrasonic examination by Doppler's method, the variation of mitral orifice blood flow rate E/A ratio.
1.3 statistical analysis
Statistical data is represented with mean ± standard deviation, adopts the t check, and there is remarkable result P＜0.05.
2 results
2.1 use patient's 17 examples of beta-blocker treatment, E/A:0.77 before the treatment ± 0.11, treatment back E/A:0.94 ± 0.18.Use patient's 15 examples of calcium ion antagonist treatment, E/A:0.76 before the treatment ± 0.18, treatment back E/A:0.95 ± 0.16.Use patient's 20 examples of drug combination preparation group treatment, E/A:0.69 before the treatment ± 0.10, treatment back E/A:0.93 ± 0.2.Adopt the patient treatment front and back E/A odds ratio of above-mentioned 3 kinds of medicines that obvious effects (P＜0.05) is more all arranged, see table 1 for details.
Three kinds of different pharmaceuticals of table 1 are to (the x-± s) relatively of E/A before and after the full patient treatment of diastolic function
3 discuss
Studies show that E/A ratio is the important indicator of the left chamber of reflection diastolic function, becomes the positive relation with left chamber diastolic function, it is impaired in various degree that E/A＜1 shows that left chamber diastolic function exists.Beta-blocker can raise beta receptor number on the myocardial cell, increases the energy in the myocardial repair, prevents calcium ion over loading in the myocardial cell.And decreased heart rate, prolong coronary artery relaxing period blood supply and ventricular filling time, improve full and compliance of myocardial relaxation phase thereby reach.Calcium ion antagonist then increases the full rate in peak, left chamber, also can improve left chamber diastolic function.Therefore, beta-blocker, calcium ion antagonist, drug combination preparation group all can make the ventricular diastole pressure-volume curve move down, and full resistance reduces, and it is full to increase left chamber, thereby reach the purpose of improving left chamber diastolic function.So the drug combination preparation group can reach the purpose of improving left chamber diastolic function.
Embodiment 1
Prescription: Radix Ginseng 200g, Radix Salviae Miltiorrhizae 267g, Radix Astragali 200g, Radix Ophiopogonis 200g, Rhizoma Chuanxiong 133g
Method for making: the Radix Ginseng powder is broken into fine powder, and is standby.Radix Salviae Miltiorrhizae or with 85% alcohol reflux secondary, each 1-3 hour, filter, merging filtrate, concentrating under reduced pressure must be carried pure extractum; All the other Radix Ophiopogonis, Rhizoma Chuanxiong, the Radix Astragali decoct with water secondary, and each 1-3 hour, collecting decoction filtered, filtrate concentrates, and adds equivalent 85% ethanol, after fully stirring, and standing over night, the elimination precipitate, filtrate recycling ethanol also is concentrated into relative density 1.30～1.36 (80 ℃), gets the water extracted immersing paste.After above-mentioned two kinds of extractum merging, add the Radix Ginseng fine powder and reach appropriate amount of starch, mix homogeneously, granulation, drying are distributed into 1000 bags, promptly.
Embodiment 2
Radix Ginseng 200g, Radix Salviae Miltiorrhizae 267g, Radix Astragali 200g, Radix Ophiopogonis 200g, Rhizoma Chuanxiong 133g, Fructus Schisandrae Chinensis 133g, Fructus Crataegi 200g
Method for making: the Radix Ginseng powder is broken into fine powder, and is standby.Radix Salviae Miltiorrhizae and Fructus Schisandrae Chinensis be with 85% alcohol reflux secondary, and each 1-3 hour, filter, merging filtrate, concentrating under reduced pressure must be carried pure extractum; All the other Radix Ophiopogonis, Rhizoma Chuanxiong, the Radix Astragali and Fructus Crataegi decoct with water secondary, each 1-3 hour, collecting decoction filters, and filtrate concentrates, add equivalent 85% ethanol, after fully stirring, standing over night, elimination precipitate, filtrate recycling ethanol also is concentrated into relative density 1.30～1.36 (80 ℃), gets the water extracted immersing paste.After above-mentioned two kinds of extractum are merged, add the Radix Ginseng fine powder and and appropriate amount of starch, mix homogeneously, drying is pulverized, and crosses 100 mesh sieves, and is encapsulated, makes 1000, promptly.
Embodiment 3
Radix Ginseng 600g, Radix Salviae Miltiorrhizae 534g, Radix Astragali 300g, Radix Ophiopogonis 200g, Rhizoma Chuanxiong 266g, Fructus Crataegi 200g
Method for making: the Radix Ginseng powder is broken into fine powder, and is standby.Radix Salviae Miltiorrhizae and Fructus Schisandrae Chinensis be with 85% alcohol reflux secondary, and each 1-3 hour, filter, merging filtrate, concentrating under reduced pressure must be carried pure extractum; All the other Radix Ophiopogonis, Rhizoma Chuanxiong, the Radix Astragali decoct with water secondary, and each 1-3 hour, collecting decoction filtered, filtrate concentrates, and adds equivalent 85% ethanol, after fully stirring, and standing over night, the elimination precipitate, filtrate recycling ethanol also is concentrated into relative density 1.30～1.36 (80 ℃), gets the water extracted immersing paste.After above-mentioned two kinds of extractum merging, add the Radix Ginseng fine powder and reach appropriate amount of starch, mix homogeneously, drying adds proper auxiliary materials and granulates, and tabletting is made 1000, promptly.
Embodiment 4
Radix Ginseng 400g, Radix Salviae Miltiorrhizae 801g, Radix Astragali 400g, Radix Ophiopogonis 200g, Rhizoma Chuanxiong 133g, Fructus Schisandrae Chinensis 399g
Method for making: the Radix Ginseng powder is broken into fine powder, and is standby.Radix Salviae Miltiorrhizae and Fructus Schisandrae Chinensis be with 85% alcohol reflux secondary, and each 1-3 hour, filter, merging filtrate, concentrating under reduced pressure must be carried pure extractum; All the other Radix Ophiopogonis, Rhizoma Chuanxiong, the Radix Astragali decoct with water secondary, and each 1-3 hour, collecting decoction filtered, filtrate concentrates, and adds equivalent 85% ethanol, after fully stirring, and standing over night, the elimination precipitate, filtrate recycling ethanol also is concentrated into relative density 1.30～1.36 (80 ℃), gets the water extracted immersing paste.After above-mentioned two kinds of extractum merging, add Radix Ginseng fine powder mix homogeneously, drying adds PEG4000 or/and 6000 heating and meltings drip system, promptly.
Claims (7)
1. a Chinese medicine composition that is used for the treatment of left ventricle diastolic malfunction is characterized in that comprising following bulk drugs: 20 parts-60 parts of Radix Ginsengs, 26.7 parts-80.1 parts of Radix Salviae Miltiorrhizaes, 20 parts-60 parts of the Radixs Astragali, 20 parts-60 parts of Radix Ophiopogonis, 13.3 parts-39.9 parts of Rhizoma Chuanxiongs.
2. according to the described Chinese medicine composition of claim 1, it is characterized in that: 40 parts of Radix Ginsengs, 53.4 parts of Radix Salviae Miltiorrhizaes, 40 parts of the Radixs Astragali, 40 parts of Radix Ophiopogonis, 26.6 parts of Rhizoma Chuanxiongs.
3. according to the described Chinese medicine composition of claim 1, it is characterized in that adding 13.3 parts-39.9 parts of Fructus Schisandrae Chinensis in the described crude drug or/and 20 parts-60 parts of Fructus Crataegis.
4. Chinese medicine composition according to claim 2 is characterized in that in the described crude drug adding 26.6 parts of Fructus Schisandrae Chinensis or/and 40 parts of Fructus Crataegis.
5. Chinese medicine composition preparation method according to claim 1 and 2 is: the Radix Ginseng powder is broken into fine powder, and is standby; Radix Salviae Miltiorrhizae reflux, extract, secondary filters, concentrates, and gets Radix Salviae Miltiorrhizae extractum; All the other Radix Ophiopogonis, Rhizoma Chuanxiong, the Radix Astragali decoct with water secondary, and filtration, concentrated back add ethanol, after the abundant stirring, and standing over night, the elimination precipitate, filtrate recycling ethanol gets the water extracted immersing paste.After above-mentioned two kinds of extractum merging, add Radix Ginseng fine powder and appropriate amount of auxiliary materials, make capsule, tablet, drop, granule according to conventional operation.
6. according to claim 3 or 4 described Chinese medicine composition preparation methoies be: the Radix Ginseng powder is broken into fine powder, and is standby.Radix Salviae Miltiorrhizae or/and Fructus Schisandrae Chinensis with 85% alcohol reflux secondary, each 1-3 hour, filter, merging filtrate, concentrating under reduced pressure must be carried pure extractum; All the other Radix Ophiopogonis, Rhizoma Chuanxiong, the Radix Astragali are or/and Fructus Crataegi decocts with water secondary, each 1-3 hour, collecting decoction filters, and filtrate concentrates, add equivalent 85% ethanol, after fully stirring, standing over night, elimination precipitate, filtrate recycling ethanol also is concentrated into relative density 1.30～1.36 (80 ℃), gets the water extracted immersing paste.After above-mentioned two kinds of extractum merging, add Radix Ginseng fine powder and appropriate amount of auxiliary materials, make capsule, tablet, drop, granule according to conventional operation.
7. according to the application of the described Chinese medicine composition of claim 1-4 in preparation treatment left chamber diastolic function medicine not.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010128459 CN101804150A (en) | 2010-03-22 | 2010-03-22 | Traditional Chinese medicine composite used for treating left ventricular diastolic dysfunction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010128459 CN101804150A (en) | 2010-03-22 | 2010-03-22 | Traditional Chinese medicine composite used for treating left ventricular diastolic dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101804150A true CN101804150A (en) | 2010-08-18 |
Family
ID=42606210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010128459 Pending CN101804150A (en) | 2010-03-22 | 2010-03-22 | Traditional Chinese medicine composite used for treating left ventricular diastolic dysfunction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101804150A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112190652A (en) * | 2020-11-03 | 2021-01-08 | 首都医科大学 | Application of traditional Chinese medicine composition in preparation of medicine for preventing and/or treating myocardial hypertrophy |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1692932A (en) * | 2005-04-11 | 2005-11-09 | 安徽科创中药天然药物研究所有限责任公司 | Method for preparing traditional Chinese medicine |
| CN1814170A (en) * | 2005-12-15 | 2006-08-09 | 贵州信邦制药股份有限公司 | Medicinal drop pills for treating cardiovascular disease and preparing method |
| CN1850185A (en) * | 2006-03-01 | 2006-10-25 | 贵州信邦远东药业有限公司 | Yixinshu Injecta for retaliation of Qi and pulse and promotion of blood circulation and removing of blood stasis, and preparing method therefor |
| CN101088546A (en) * | 2006-06-13 | 2007-12-19 | 葛浩斌 | Heart-benefiting Yixinshu micropill and its prepn process |
-
2010
- 2010-03-22 CN CN 201010128459 patent/CN101804150A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1692932A (en) * | 2005-04-11 | 2005-11-09 | 安徽科创中药天然药物研究所有限责任公司 | Method for preparing traditional Chinese medicine |
| CN1814170A (en) * | 2005-12-15 | 2006-08-09 | 贵州信邦制药股份有限公司 | Medicinal drop pills for treating cardiovascular disease and preparing method |
| CN1850185A (en) * | 2006-03-01 | 2006-10-25 | 贵州信邦远东药业有限公司 | Yixinshu Injecta for retaliation of Qi and pulse and promotion of blood circulation and removing of blood stasis, and preparing method therefor |
| CN101088546A (en) * | 2006-06-13 | 2007-12-19 | 葛浩斌 | Heart-benefiting Yixinshu micropill and its prepn process |
Non-Patent Citations (5)
| Title |
|---|
| 《中国医院用药评价与分析》 20091231 王庆春等 益心舒胶囊治疗冠心病心绞痛100例临床观察 942-943 1-7 第9卷, 第12期 2 * |
| 《中国药房》 20091231 刘川玉等 益心舒胶囊对慢性心力衰竭患者心功能及Ang Ⅱ和TNF - alpha的影响研究 2385-2387 1-7 第20卷, 第30期 2 * |
| 《中西医结合心脑血管病杂志》 20090430 陈伟 益心舒胶囊早期应用对充血性心力衰竭患者心功能及细胞因子的影响 387-388 1-7 第7卷, 第4期 2 * |
| 《中西医结合心脑血管病杂志》 20100310 李水晴等 益心舒胶囊治疗左室舒张功能不全的临床研究 281-282 1-7 第8卷, 第3期 2 * |
| 《白求恩军医学院学报》 20100228 葛海柱等 益心舒胶囊治疗慢性充血性心力衰竭的临床观察 24-25 1-7 第8卷, 第1期 2 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112190652A (en) * | 2020-11-03 | 2021-01-08 | 首都医科大学 | Application of traditional Chinese medicine composition in preparation of medicine for preventing and/or treating myocardial hypertrophy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103285231A (en) | Medicine composition for diabetes adjunctive therapy and preparation method thereof | |
| CN103083531A (en) | Drug for treating diabetes | |
| CN101524471A (en) | Pharmaceutical composition for treating diabetes and preparation method thereof | |
| CN102940801A (en) | Traditional Chinese medicine composition for treating hypertension | |
| CN103623341A (en) | Drug for treating hypertension and cardiovascular and cerebrovascular diseases caused by hypertension | |
| CN100558347C (en) | Ginseng-astragalus dispersion tablet formulation and preparation technology thereof | |
| CN106266558A (en) | A kind of Halth-care composition of resisting fatigue and preparation method thereof | |
| CN103933346B (en) | A kind of compound for reducing blood suger and preparation method thereof | |
| CN101856405B (en) | Medicinal composition for treating type II diabetes mellitus and preparation method thereof | |
| CN103768407A (en) | Compound blood glucose reducing capsules and preparation method thereof | |
| CN103006989B (en) | Medical composition for treating diabetic nephropathy | |
| CN108498708A (en) | A kind of Chinese medicine composition for treating diabetes | |
| CN101322792A (en) | Applications of Chinese medicinal composition in preparing medicament for improving function of vascular endothelium | |
| CN102488838B (en) | Traditional Chinese medicine composition used for treating viral myocarditis | |
| CN101491627A (en) | Traditional Chinese medicine composition II type diabetes and hyperlipemia | |
| CN100558349C (en) | Ginseng-astragalus capsule formulation and preparation technology thereof | |
| CN102626510B (en) | Traditional Chinese medicine composite for treating diabetic cardiopathy and preparation method and applications thereof | |
| CN101804150A (en) | Traditional Chinese medicine composite used for treating left ventricular diastolic dysfunction | |
| CN101804141A (en) | Chinese medicine compound for preventing and curing hypertension, hyperlipidemia, hyperglycemia and complications thereof | |
| CN102018852A (en) | Ginseng and coptis capsule for quenching thirsty and reducing blood sugar and preparation process | |
| CN100534486C (en) | Chinese medicinal preparation for treating proteinuria caused by diabetic nephropathy and preparation method thereof | |
| CN108524762B (en) | Pharmaceutical composition for treating chronic heart failure and application thereof | |
| CN104706736B (en) | A kind of Chinese patent drug cardiac stimulant recovering capsule of chronic heart failure and preparation method thereof | |
| CN104055963A (en) | Fat loss traditional Chinese medicine composition and preparation method thereof | |
| CN103263581A (en) | Shuangshen capsule for reducing blood sugar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20100818 |